BBI - Brickell Biotech announces 1-for-45 reverse stock split
- Brickell Biotech ( NASDAQ: BBI ) has announced that at the Co.’s stockholders approved a reverse stock split of the Co.'s common stock at a ratio between 1-to-10 and 1-to-45 and will become effective on July 5, 2022.
- The Co.'s common stock will begin trading on a split-adjusted basis at the opening of the market on July 5, 2022, under a new CUSIP number, 10802T 204.
- The 1-for-45 reverse stock split will reduce the number of outstanding shares of Company common stock from ~121.1M shares to ~2.7M shares.
- The purpose of the split is to raise the per-share trading price of the Co.'s common stock, which is intended to result in its regaining compliance.
For further details see:
Brickell Biotech announces 1-for-45 reverse stock split